US8044074B2 - Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them - Google Patents

Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them Download PDF

Info

Publication number
US8044074B2
US8044074B2 US11/954,396 US95439607A US8044074B2 US 8044074 B2 US8044074 B2 US 8044074B2 US 95439607 A US95439607 A US 95439607A US 8044074 B2 US8044074 B2 US 8044074B2
Authority
US
United States
Prior art keywords
carbon atoms
formula
pyridin
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US11/954,396
Other languages
English (en)
Other versions
US20080188477A1 (en
Inventor
Joachim Brendel
Heinrich Christian Englert
Klaus Wirth
Michael Wagner
Jean-Marie Ruxer
Fabienne Pilorge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Assigned to SANOFI-AVENTIS reassignment SANOFI-AVENTIS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PILORGE, FABIENNE, WIRTH, KLAUS, RUXER, JEAN-MARIE, WAGNER, MICHAEL, BRENDEL, JOACHIM, ENGLERT, HEINRICH
Publication of US20080188477A1 publication Critical patent/US20080188477A1/en
Application granted granted Critical
Publication of US8044074B2 publication Critical patent/US8044074B2/en
Assigned to SANOFI reassignment SANOFI CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SANOFI-AVENTIS
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Definitions

  • the invention relates to compounds of formula I,
  • R1, R2, R3, R4, R5, R6 and X have the meanings stated below, to their preparation and their use, in particular in pharmaceuticals.
  • the compounds of the invention of formula I have not previously been described. They act on the so-called Kv1.5 potassium channel and inhibit a potassium current which is designated the ultra-rapidly activating delayed rectifier in the human atrium. In addition, the compounds also act on other atrium-specific potassium channels such as the acetylcholine-dependent potassium channel KACh, and the 2P domain potassium channel TASK-1.
  • the compounds are therefore very particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
  • Atrial fibrillation (AF) and atrial flutter are the commonest sustained cardiac arrhythmias.
  • the incidence increases with increasing age and frequently leads to fatal sequelae such as, for example, stroke.
  • AF affects for example about 3 million Americans and leads to more than 80 000 strokes each year in the USA.
  • class I and III antiarrhythmics currently in use can reduce the rate of recurrence of AF, their use is restricted owing to their potential proarrhythmic side effects. There is for this reason a great medical need for better medicaments for treating atrial arrhythmias to be developed.
  • reentry depolarization waves underlie most supraventricular arrhythmias. Such reentries occur if the cardiac tissue has a slow conductivity and, at the same time, very short refractory periods.
  • the increase in the myocardial refractory period by prolonging the action potential is an accepted mechanism for terminating arrhythmias and preventing their development.
  • the length of the action potential is substantially determined by the extent of repolarizing K + currents which flow out of the cell through the various K + channels. Particularly great importance is ascribed in this connection to the so-called delayed rectifier I K which consists of 3 different components: IK r , IK s and IK ur .
  • class III antiarrhythmics for example dofetilide or d-sotalol
  • IK r rapidly activating potassium channel
  • Mathematical models of the human action potential suggest that the positive effect of a blockade of the IK ur ought to be particularly pronounced precisely under the pathological conditions of chronic atrial fibrillation (M. Courtemanche, R. J. Ramirez, S, Nattel, Cardiovascular Research 1999, 42, 477-489: “Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model”).
  • IK ur plays a significant role in the human atrium, but not in the ventricle. For this reason, if the IK ur current is inhibited, the risk of a proarrhythmic effect on the ventricle is precluded from the outset, in contrast to blockade of IK r or IK s (Z. Wang et al, Circ. Res. 73, 1993, 1061-1076: “Sustained Depolarisation-Induced Outward Current in Human Atrial Myocytes”; G.-R. Li et al, Circ. Res.
  • Antiarrhythmics which act by atrium-selective blockade of the IK ur current or Kv1.5 channel have not, however, been available on the market to date. Although a blocking effect on the Kv1.5 channel has been described for numerous active pharmaceutical ingredients (for example quinidine, bupivacaine or propafenone), the Kv1.5 blockade in each of these cases represents only a side effect in addition to other main effects of the substances.
  • active pharmaceutical ingredients for example quinidine, bupivacaine or propafenone
  • Kv1.5 channel blockers A number of patent applications in recent years have described various substances as Kv1.5 channel blockers. A compilation and detailed discussion of these substances has recently been published (J. Brendel, S. Peukert; Curr. Med. Chem.—Cardiovascular & Hematological Agents, 2003, I, 273-287; “Blockers of the Kv1.5 Channel for the Treatment of Atrial Arrhythmias”).
  • all Kv1.5 blockers disclosed to date and described therein have entirely different types of structures than the compounds of the invention in this application.
  • no clinical data on the effect and tolerability in humans have been disclosed to date for any of the compounds disclosed to date. Since experience has shown that only a small proportion of active ingredients successfully overcome all the clinical hurdles from preclinical research to the medicament, there continues to be a need for novel, promising substances.
  • the compounds of formula I and/or their pharmaceutically acceptable salts also act on the acetylcholine-activated potassium channel KACh and on the TASK-1 channel, which likewise predominantly occur in the atrium (Krapivinsky G., Gordon E. A., Wickman K., Velimirovic B., Krapivinsky L., Clapham D. E.: “The G-protein-gated atrial K + channel I KACh is a heteromultimer of two inwardly rectifying K + -channel proteins”, Nature 374 (1995) 135-141; Liu, W., Saint, D.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can therefore be used as novel antiarrhythmics with a particularly advantageous safety profile.
  • the compounds are suitable in particular for the treatment of supraventricular arrhythmias, for example atrial fibrillation or atrial flutter.
  • the compounds of formula I and/or pharmaceutically acceptable salts thereof can also be employed for the treatment and prevention of diseases where the atrium-specific potassium channels, for example the Kv1.5, the KACh and/or the TASK-1, are only partially inhibited, for example by using a lower dosage.
  • the atrium-specific potassium channels for example the Kv1.5, the KACh and/or the TASK-1
  • the compounds of formula I and/or their pharmaceutically acceptable salts can be employed to produce medicaments with a K + channel-blocking effect for the therapy and prophylaxis of K + channel-mediated diseases.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can further be used for the therapy or prophylaxis of cardiac arrhythmias which can be abolished by prolonging the action potential.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can be employed for terminating existent atrial fibrillation or flutter to restore the sinus rhythm (cardioversion).
  • the substances reduce the susceptibility to the development of new fibrillation events (maintenance of sinus rhythm, prophylaxis). It has further been observed that the substances are effective for preventing life-threatening ventricular arrhythmias (ventricular fibrillation) and are able to protect from sudden heart death without, however, simultaneously bringing about an unwanted prolongation of the so-called QT interval.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can be employed for producing a medicament for the therapy or prophylaxis of reentry arrhythmias, of supraventricular arrhythmias, atrial fibrillation and/or atrial flutter.
  • the compounds of formula I and/or their pharmaceutically acceptable salts are further suitable for producing a medicament for the therapy or prophylaxis of heart failure, in particular of diastolic heart failure and for increasing atrial contractility.
  • the compounds of formula I and/or pharmaceutically acceptable salts thereof inhibit TASK potassium channels, for example the subtypes TASK-1 and TASK-3, in particular the subtype TASK-1. Because of the TASK-inhibitory properties, the compounds of formula I and/or their pharmaceutically acceptable salts are suitable for the prevention and treatment of diseases caused by activation or by an activated TASK-1, and of diseases caused secondarily by the TASK-1-related damage.
  • the compounds of formula I and/or their pharmaceutically acceptable salts are also suitable for producing a medicament for the therapy or prophylaxis of respiratory disorders, especially sleep apneas, neurodegenerative disorders and cancers, for example sleep-related respiratory disorders, central and obstructive sleep apneas, Cheyne-Stoke's breathing, snoring, impaired central respiratory drive, sudden infant death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders following long-term ventilation, respiratory disorders associated with altitude adaptation, acute and chronic pulmonary disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancers, breast cancer, lung cancer, colon cancer and prostate cancer.
  • the present invention relates to compounds of formula I
  • R1 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl or 4-pyridazinyl, in particular phenyl, where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , methylsulfonyl, CF 3 , alkyl having 1,
  • a further embodiment describes compounds of formula I in which R2 is phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl or 4-pyridazinyl, in particular phenyl, where each of these aryl radicals is unsubstituted or substituted by 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, I, CN, alkoxy having 1, 2, 3 or 4 carbon atoms, OCF 3 , methylsulfonyl, CF 3 , alkyl
  • a further embodiment describes compounds of formula I in which R3 is C p H 2p —R7, where p is 0, 1, 2 or 3, in particular 0 or 1, for example 1, and R7 is CH 3 , cycloalkyl having 3 or 4 carbon atoms or phenyl, for example cyclopropyl or phenyl, where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, Br, CN, alkyl having 1 or 2 carbon atoms and alkoxy having 1 or 2 carbon atoms, for example selected from the group consisting of methoxy and CN.
  • a further embodiment describes compounds of formula I in which R4 is hydrogen or methyl, for example hydrogen.
  • a further embodiment describes compounds of formula I in which R5 is hydrogen or methyl, for example hydrogen.
  • a further embodiment describes compounds of formula I in which R6 is hydrogen, F or alkyl having 1 or 2 carbon atoms, for example hydrogen or fluorine.
  • a further embodiment describes compounds of formula I in which X is CH.
  • a further embodiment describes compounds of formula I in which X is N.
  • the compounds of formula I may exist in stereoisomeric forms.
  • the centers of asymmetry which are present may independently of one another have the S configuration or the R configuration.
  • the invention includes all possible stereoisomers, for example enantiomers or diastereomers, and mixtures of two or more stereoisomeric forms, for example enantiomers and/or diastereomers, in any ratios.
  • the invention thus includes for example enantiomers in enantiopure form, both as levorotatory and as dextrorotatory antipodes, and in the form of mixtures of the two enantiomers in various ratios or in the form of racemates.
  • Individual stereoisomers can be prepared as desired by fractionating a mixture by conventional methods or for example by stereoselective synthesis.
  • the present invention also includes all tautomeric forms of compounds of formula I.
  • the present invention further includes derivatives of compounds of formula I, for example solvates, such as hydrates and alcohol adducts, esters, prodrugs and other physiologically acceptable derivatives of the compounds of formula I, and active metabolites of the compounds of formula I.
  • the invention likewise includes all crystal modifications of the compounds of formula I.
  • Alkyl radicals and alkylene radicals may be straight-chain or branched. This also applies to the alkylene radicals of formula C p H 2p . Alkyl radicals and alkylene radicals may also be straight-chain or branched if they are substituted or are present in other radicals, for example in an alkoxy radical or in a fluorinated alkyl radical. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • the divalent radicals derived from these radicals for example methylene, 1,1-ethylene, 1,2-ethylene, 1,1-propylene, 1,2-propylene, 2,2-propylene, 1,3-propylene, 1,1-butylene, 1,4-butylene, etc. are examples of alkylene radicals.
  • One or more, for example 1, 2, 3, 4, 5, 6, 7, 8, or 9 hydrogen atoms in alkyl and alkylene radicals may be replaced by fluorine atoms.
  • Substituted alkyl radicals may be substituted in any positions.
  • Cycloalkyl radicals may likewise be branched.
  • Examples of cycloalkyl radicals having 3 to 7 carbon atoms are cyclopropyl, cyclobutyl, 1-methylcyclopropyl, 2-methylcyclopropyl, cyclopentyl, 2-methylcyclobutyl, 3-methylcyclobutyl, cyclopentyl, cyclohexyl, 2-methylcyclohexyl, 3-methylcyclohexyl, 4-methylcyclohexyl, cycloheptyl etc.
  • One or more, for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 hydrogen atoms in cycloalkyl radicals may be replaced by fluorine atoms.
  • cycloalkyl radicals may be substituted in any positions.
  • Cycloalkyl radicals may also be in branched form as alkylcycloalkyl or cycloalkylalkyl, for example methylcyclohexyl or cyclohexylmethyl.
  • Phenyl radicals may be unsubstituted or substituted one or more times, for example once, twice or three times, by identical or different radicals. If a phenyl radical is substituted, it preferably has one or two identical or different substituents. Monosubstituted phenyl radicals may be substituted in position 2, 3 or 4, disubstituted in 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-, position trisubstituted in 2,3,4-, 2,3,5-, 2,3,6-, 2,4,5-, 2,4,6- or 3,4,5-position.
  • N-containing heteroaromatic systems such as pyridyl, quinolinyl, pyrimidinyl or pyrazinyl, the naphthyl radical and the thienyl radical, for example for 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 3-pyridazinyl or 4-pyridazinyl.
  • the invention also includes the corresponding physiologically, pharmaceutically or toxicologically acceptable salts, especially the pharmaceutically acceptable salts, but also the trifluoroacetates.
  • the compounds of formula I which have one or more basic, i.e. protonatable, groups or comprise one or more basic heterocyclic rings, can also be used in the form of their physiologically tolerated acid addition salts with inorganic or organic acids, for example as hydrochlorides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, malates, gluconates etc.
  • Salts can be obtained from compounds of formula I by conventional processes, for example by combining with an acid in a solvent or dispersant or else by anion exchange from other salts.
  • the compounds of formula I may also be deprotonated on an acidic group and be used for example as alkali metal salts, preferably sodium or potassium salts, or as ammonium salts, for example as salts with ammonia or organic amines or amino acids.
  • the invention further relates to processes for preparing the compounds of formula I.
  • the compounds of formula I can be prepared by various chemical processes, where R1, R2, R3, R4, R5, R6 and X have the same meaning as in compounds of formula I.
  • a further preparation process is depicted in scheme 2 and relates to the addition of appropriately compounds of formula IX on aldehydes or ketones of formula VIII using a suitable base with subsequent reaction of the resulting alcohol function of formula V with a compound of formula VI to give a compound of formula Ib, where X1 has the abovementioned meanings.
  • a further method for preparing the compounds of formula I is depicted in scheme 3 below.
  • This method uses the ring opening of R1 and R2 substituted epoxides of formula XI by suitable compounds of formula XII with base catalysis as key step and affords, in contrast to the other methods, the products in diastereoisomerically pure form.
  • the resulting alcohol of formula Vb is subsequently reacted with a compound of formula VI to give the compound of formula Ic, where X1 has the abovementioned meanings.
  • the starting compounds described in the synthetic methods such as the compounds of formula II, III, VI, VIa, VII, IX, XI and XII can be purchased or can be prepared by or analogous to processes described in the literature and known to the skilled worker.
  • the compounds of the invention of formula I and their pharmaceutically acceptable salts can thus be used on animals, preferably on mammals, and in particular on humans, as pharmaceuticals on their own, in mixtures with one another or in the form of pharmaceutical preparations.
  • the present invention also relates to the compounds of formula I and their pharmaceutically acceptable salts for use in the therapy and prophylaxis of the abovementioned diseases and to their use for producing medicaments for the abovementioned diseases and medicaments with a K + channel-blocking action.
  • a pharmaceutical preparation comprising an effective amount of a compound of formula I and/or of its pharmaceutically acceptable salts, together with pharmaceutically acceptable carriers and additives, alone or in combination with other pharmacological active ingredients or pharmaceuticals.
  • the pharmaceutical preparations normally comprise from 0.1 to 90 percent by weight of the compounds of formula I and/or their pharmaceutically acceptable salts.
  • the pharmaceutical preparations can be produced in a manner known per se. For this purpose, the compounds of formula I and/or their pharmaceutically acceptable salts are converted together with one or more solid or liquid pharmaceutical vehicles and/or excipients and, if desired, in combination with other pharmaceutical active ingredients into a suitable dosage form, which can then be used as pharmaceutical in human medicine or veterinary medicine.
  • compositions which comprise a compound of formula I and/or its pharmaceutically acceptable salts can moreover be administered for example orally, parenterally, intravenously, rectally, percutaneously, topically or by inhalation, and the preferred administration depends on the individual case, for example on the particular manifestation of the disorder.
  • the compounds of formula I can moreover be used alone or together with pharmaceutical excipients, in particular both in veterinary and in human medicine.
  • the pharmaceuticals comprise active ingredients of formula I and/or their pharmaceutically acceptable salts generally in an amount of from 0.01 mg to 1 g per dose unit.
  • excipients are suitable for the desired pharmaceutical formulation.
  • solvents gel formers, suppository bases, tablet excipients and other active substance carriers it is possible to use for example antioxidants, dispersants, emulsifiers, antifoams, masking flavors, preservatives, solubilizers, agents for achieving a depot effect, buffer substances or colorants.
  • the active compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable presentations such as tablets, coated tablets, two-piece capsules, aqueous, alcoholic or oily solutions.
  • suitable inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation can take place both as dry and as wet granules.
  • Suitable as oily carriers or as solvents are, for example, vegetable or animal oils such as sunflower oil or fish liver oil.
  • Suitable solvents for aqueous or alcoholic solutions are, for example, water, ethanol or sugar solutions or mixtures thereof.
  • further excipients, also for other administration forms are polyethylene glycols and polypropylene glycols.
  • the active compounds are converted if desired with the substances usual for this purpose, such as solubilizers, emulsifiers or further excipients, into a solution, suspension or emulsion.
  • the compounds of formula I and/or their pharmaceutically acceptable salts may also be lyophilized and the resulting lyophilizates be used, for example, for producing products for injection or infusion.
  • suitable solvents are: water, physiological saline or alcohols, for example ethanol, propanol, glycerol, as well as sugar solutions such as glucose or mannitol solutions, or else mixtures of the various solvents mentioned.
  • Suitable as pharmaceutical formulations for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active ingredient of formula I or their pharmaceutically acceptable salts in a pharmaceutically acceptable solvent, such as in particular ethanol or water, or a mixture of such solvents.
  • a pharmaceutically acceptable solvent such as in particular ethanol or water, or a mixture of such solvents.
  • the formulation may if required also comprise other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas.
  • Such a preparation comprises the active ingredient normally in a concentration of about 0.1 to 10, in particular of about 0.3 to 3 percent by weight.
  • the dosage of the active ingredient to be administered or of the pharmaceutically acceptable salts thereof depends on the individual case and should be adapted to the circumstances of the individual case as usual for an optimal effect. Thus, it naturally depends on the frequency of administration and on the potency and duration of action of the particular compounds employed for therapy or prophylaxis, but also on the type and severity of the disease to be treated, and on the gender, age, weight and individual response of the human or animal to be treated, and on whether therapy is acute or prophylactic.
  • the daily dose of a compound of formula I and/or its pharmaceutically acceptable salts for a patient weighing about 75 kg is normally at least 0.001 mg/kg to 100 mg/kg of body weight, preferably 0.01 mg/kg to 20 mg/kg. Even higher dosages may also be necessary for acute episodes of the disease, for example in an intensive care unit. Up to 800 mg per day may be necessary, especially on i.v. use, for instance for an infarct patient in an intensive care unit.
  • the dose may be in the form of a single dose or be divided into a plurality, for example two, three or four, single doses. Parenteral administration by injection or infusion, for example a continuous intravenous infusion, may also be advantageous, especially in the treatment of acute cases of cardiac arrhythmias, for example in an intensive care unit.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can also be combined with other pharmaceutical active ingredients to achieve an advantageous therapeutic effect.
  • advantageous combinations with substances acting on the cardiovascular system are possible in the treatment of cardiovascular disorders.
  • Suitable examples of such combination partners advantageous for cardiovascular disorders are other antiarrhythmics, i.e.
  • class I, class II or class III antiarrhythmics such as, for example, IK r channel blockers, for example dofetilide, or additionally substances which reduce blood pressure, such as ACE inhibitors (for example enalapril, captopril, ramipril), angiotensin antagonists, K + channel activators, and alpha- and beta-receptor blockers, but also sympathomimetic and adrenergic compounds, and Na + /H + exchange inhibitors, calcium channel antagonists, phosphodiesterase inhibitors and other substances with a positive inotropic effect, such as, for example, digitalis glycosides, or diuretics.
  • ACE inhibitors for example enalapril, captopril, ramipril
  • angiotensin antagonists K + channel activators
  • alpha- and beta-receptor blockers but also sympathomimetic and adrenergic compounds
  • Na + /H + exchange inhibitors sodium + /H + exchange inhibitors
  • the compounds of formula I can be prepared by various processes. The preparation methods used to prepare the examples are described below, where R1, R2, R3, R4, R5, R6 and X have the same meaning as in compounds of formula I.
  • a) The compounds of formula Va were dissolved in a dipolar aprotic solvent such as, for example, DMSO or DMF, and 1-20 mole equivalents of a base such as, for example, powdered NaOH or NaH were added.
  • a compound of formula VI such as, for example, cyclopropylmethyl bromide or 4-CN-fluorobenzene, where X1 is defined for example as halogen such as fluorine, chlorine, bromine or iodine, in particular fluorine or bromine, were added at room temperature.
  • the mixture was stirred at room temperature for 1-10 hours until conversion was complete, and further equivalents of the compound of formula VI were added where appropriate (variant Aa).
  • the reaction mixture was usually diluted with water and, in the event that the products do not separate out as crystals, extracted with ethyl acetate and purified where appropriate by chromatography.
  • a) 1 equivalent of a compound of formula V was dissolved in a dipolar aprotic solvent such as, for example, DMSO or DMF, and 1-20 mole equivalents of a base such as, for example, powdered NaOH or NaH were added.
  • a compound of formula VI such as, for example, cyclopropylmethyl bromide or 4-CN-fluorobenzene, where X1 is defined for example as halogen such as fluorine, chlorine, bromine or iodine, in particular fluorine or bromine, were added at room temperature.
  • the mixture was stirred at room temperature for 1-10 hours until conversion was complete, and further equivalents of the compound of formula VI were added where appropriate (variant Ba).
  • the reaction mixture was usually diluted with water and, in the event that the products do not separate out as crystals, extracted with ethyl acetate and purified where appropriate by chromatography.
  • a) 1 equivalent of a compound of formula Vb was dissolved in a dipolar aprotic solvent such as, for example, DMSO or DMF, and 1-20 mole equivalents of a base such as, for example, powdered NaOH or NaH were added.
  • a compound of formula VI such as, for example, cyclopropylmethyl bromide or 4-CN-fluorobenzene, where X1 is defined for example as halogen such as fluorine, chlorine, bromine or iodine, in particular fluorine or bromine, were added at room temperature.
  • the mixture was stirred at room temperature for 1-10 hours until conversion was complete, and further equivalents of the compound of formula VI were added where appropriate (variant Ca).
  • the reaction mixture was usually diluted with water and, in the event that the products do not separate out as crystals, extracted with ethyl acetate and purified where appropriate by chromatography.
  • the starting compounds described in the synthetic methods such as the compounds of formula II, III, VI, VIa, VII, IX, XI and XII can be purchased or can be prepared by or analogous to processes described in the literature and known to the skilled worker.
  • Racemic cis-stilbene oxide (100 mg, 0.51 mmol) was dissolved in absolute DMF, and 18.36 mg of a suspension of sodium hydride (90% in oil) and 72.75 mg of 2-hydroxypyridine were added, and the mixture was stirred at 80° C. under argon for 4 hours. The mixture was worked up with water/ethyl acetate and chromatographed on silica gel with ethyl acetate/n-heptane 1:1.
  • 1-(2-Hydroxy-1,2-diphenylethyl)-1H-pyridin-2-one was obtained first, 42 mg, 28% as sterically uniform compound which, on the basis of the known steric course of epoxide ring openings under basic conditions, was assigned the trans arrangement of the hydroxy group and the pyridine ring, corresponding to a relative 1R′,2R′ configuration of centers 1 and 2:
  • stage b) The intermediate obtained in stage a) was dissolved in 0.5 ml of methanol and treated with sodium borohydride (50 mg) for 1 hour.
  • the usual workup resulted in a mixture of the diastereoisomeric alcohols:
  • stage b) The intermediate obtained in stage b) was reacted with bromomethylcyclopropane under the conditions described in example 3 to give the desired final product. Chromatography on 10 g of silica gel were employed for purification, resulting in 16 mg of 2-[2-(4-chlorophenyl)-2-cyclopropylmethoxy-1-phenylethyl]-2H-pyridazin-3-one.
  • Kv1.5 channels were expressed in xenopus oocytes. For this purpose, firstly oocytes were isolated from Xenopus laevis and defolliculated. Kv1.5-encoding RNA synthesized in vitro was then injected into these oocytes. After Kv1.5 protein expression for 1-7 days, Kv1.5 currents were measured on the oocytes using the two-microelectrode voltage clamp technique. The Kv1.5 channels were in this case usually activated with voltage jumps lasting 500 ms to 0 mV and 40 mV.
  • Human TASK-1 channels were expressed in xenopus oocytes. For this purpose, firstly oocytes were isolated from Xenopus laevis and defolliculated. TASK-1-encoding RNA synthesized in vitro was then injected into these oocytes. After TASK-1 protein expression for 2 days, TASK-1 currents were measured on the oocytes using the two-microelectrode voltage clamp technique. The TASK-1 channels were in this case usually activated with voltage jumps lasting 250 ms to 40 mV.
  • IC 50 half-maximum inhibitory concentrations
  • the atrium was stimulated with a square-wave pulse of 1 to 4 volts lasting 1 to 3 milliseconds with a frequency of 1 Hz.
  • the action potential was recorded using a glass microelectrode which was filled with 3 mol/l of KCl.
  • the electrical signal was picked up by an amplifier (model 309 microelectrode amplifier, Hugo Sachs, March-Hugstetten, Germany) and stored and analyzed in a computer.
  • Experimental outline after an equilibration time of 30 min, 1 ⁇ mol/l carbachol was added in order to activate the K ACh ion channels by stimulating muscarinic receptors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/954,396 2005-06-22 2007-12-12 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them Expired - Fee Related US8044074B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102005028862A DE102005028862A1 (de) 2005-06-22 2005-06-22 Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE102005028862 2005-06-22
DE102005028862.6 2005-06-22
PCT/EP2006/005578 WO2006136304A1 (en) 2005-06-22 2006-06-10 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005578 Continuation WO2006136304A1 (en) 2005-06-22 2006-06-10 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them

Publications (2)

Publication Number Publication Date
US20080188477A1 US20080188477A1 (en) 2008-08-07
US8044074B2 true US8044074B2 (en) 2011-10-25

Family

ID=36869946

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/954,396 Expired - Fee Related US8044074B2 (en) 2005-06-22 2007-12-12 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them

Country Status (17)

Country Link
US (1) US8044074B2 (ko)
EP (1) EP1896416B1 (ko)
JP (1) JP2008543896A (ko)
KR (1) KR20080018903A (ko)
CN (1) CN101203493B (ko)
AT (1) ATE411291T1 (ko)
AU (1) AU2006261316B2 (ko)
BR (1) BRPI0612515A2 (ko)
CA (1) CA2610075A1 (ko)
DE (2) DE102005028862A1 (ko)
DK (1) DK1896416T3 (ko)
ES (1) ES2316080T3 (ko)
HK (1) HK1120794A1 (ko)
IL (1) IL188092A0 (ko)
MX (1) MX2007015970A (ko)
PT (1) PT1896416E (ko)
WO (1) WO2006136304A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006049527A1 (de) * 2006-10-20 2008-04-24 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und TASK-3 Ionenkanals
CA2735460A1 (en) * 2008-08-29 2010-03-04 The Uab Research Foundation Novel anti-arrhythmia agent
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
US9034897B2 (en) 2011-09-12 2015-05-19 Sanofi Indanyl-substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them
EA023648B1 (ru) 2011-09-12 2016-06-30 Санофи ИНДАНИЛЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРО-1H-ПИРАЗОЛО[4,3-с]ПИРИДИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ
WO2013037914A1 (en) 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
ES2559450T3 (es) * 2011-09-16 2016-02-12 Sanofi 4,5,6,7-Tetrahidro-1H-pirazolo[4,3-c]piridinas sustituidas, su uso como medicamento, y preparaciones farmacéuticas que las comprenden
KR102017362B1 (ko) * 2012-02-03 2019-09-02 사노피 축합 피롤디카복사미드 및 약제로서의 그의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235886A1 (en) 2003-01-31 2004-11-25 Charifson Paul S. Gyrase inhibitors and uses thereof
US20050038247A1 (en) 2003-01-31 2005-02-17 Charifson Paul S. Gyrase inhibitors and uses thereof
US20050054673A1 (en) 2003-09-08 2005-03-10 Aventis Pharma Deutschland Gmbh Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
WO2005046578A2 (en) 2003-09-23 2005-05-26 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US20070027177A1 (en) 2003-09-23 2007-02-01 Trotter B W Isoquinolinone potassium channel inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9313330D0 (en) * 1993-06-28 1993-08-11 Fujisawa Pharmaceutical Co New compound and its preparation
KR100257129B1 (ko) * 1993-09-11 2000-05-15 성재갑 신규 세팔로스포린계 항생제 및 이의 제조방법
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235886A1 (en) 2003-01-31 2004-11-25 Charifson Paul S. Gyrase inhibitors and uses thereof
US20050038247A1 (en) 2003-01-31 2005-02-17 Charifson Paul S. Gyrase inhibitors and uses thereof
US7495014B2 (en) 2003-01-31 2009-02-24 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US20050054673A1 (en) 2003-09-08 2005-03-10 Aventis Pharma Deutschland Gmbh Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
WO2005046578A2 (en) 2003-09-23 2005-05-26 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
US20070027177A1 (en) 2003-09-23 2007-02-01 Trotter B W Isoquinolinone potassium channel inhibitors

Also Published As

Publication number Publication date
WO2006136304A1 (en) 2006-12-28
MX2007015970A (es) 2008-03-06
DE602006003224D1 (de) 2008-11-27
ATE411291T1 (de) 2008-10-15
CN101203493A (zh) 2008-06-18
EP1896416B1 (en) 2008-10-15
CN101203493B (zh) 2011-09-07
KR20080018903A (ko) 2008-02-28
HK1120794A1 (en) 2009-04-09
EP1896416A1 (en) 2008-03-12
AU2006261316A1 (en) 2006-12-28
AU2006261316B2 (en) 2011-09-15
IL188092A0 (en) 2008-03-20
ES2316080T3 (es) 2009-04-01
JP2008543896A (ja) 2008-12-04
DE102005028862A1 (de) 2007-01-11
DK1896416T3 (da) 2009-02-23
US20080188477A1 (en) 2008-08-07
BRPI0612515A2 (pt) 2010-11-30
CA2610075A1 (en) 2006-12-28
PT1896416E (pt) 2008-12-16

Similar Documents

Publication Publication Date Title
US8044074B2 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
US7825264B2 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
US11672799B2 (en) 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions
EP1581505B1 (en) Pyridazinone derivatives as gsk-3beta inhibitors
DE69434041T2 (de) Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
JP5277256B2 (ja) ｍａｘｉ−Ｋチャネル開口薬としてのピリミジン、ピリジン及びトリアジン誘導体
KR970005927B1 (ko) 디아릴메틸피페리딘 또는 피페라진의 피리딘 및 피리딘 n-옥사이드 유도체, 이를 함유하는 약제학적 조성물 및 이의 제조방법
JP2008536950A (ja) 置換ヘテロアリールのｃｂ１拮抗薬
CZ373096A3 (en) Trisubstituted phenyl derivatives, process of their preparation and pharmaceutical compositions containing thereof
US20190062308A1 (en) 1,3,5-triazine derivative and method of using same
JP2002514196A (ja) 置換ピリミジノンおよびピリドン化合物ならびに使用方法
JPS6126539B2 (ko)
JP2003501416A (ja) 医薬組成物およびその使用法
JPWO2005087749A1 (ja) ２−アミノキナゾリン誘導体
KR102441864B1 (ko) 괴사의 억제제로서 헤테로아릴 화합물, 이의 조성물 및 이의 용도
KR20150023766A (ko) 아릴에틴일 유도체
AU2002314809A1 (en) 5-substituted-2-arylpyridines as CRF1 modulators

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI-AVENTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRENDEL, JOACHIM;ENGLERT, HEINRICH;WIRTH, KLAUS;AND OTHERS;REEL/FRAME:020911/0050;SIGNING DATES FROM 20080225 TO 20080314

Owner name: SANOFI-AVENTIS, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRENDEL, JOACHIM;ENGLERT, HEINRICH;WIRTH, KLAUS;AND OTHERS;SIGNING DATES FROM 20080225 TO 20080314;REEL/FRAME:020911/0050

ZAAA Notice of allowance and fees due

Free format text: ORIGINAL CODE: NOA

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
AS Assignment

Owner name: SANOFI, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:SANOFI-AVENTIS;REEL/FRAME:028413/0927

Effective date: 20110511

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20231025